Study Title: KRT-232-115: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), or Post Essential Thrombocythemia (post ET MF) That Have a Suboptimal Response to Ruxolitinib
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Coltoff, Alexander, at coltoff@musc.edu.Study Coordinator, Schaefer, Matthew, at schaefma@musc.edu.Trial opened at the following institutions: Medical University of South Carolina